Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Wednesday reported promising preclinical data for its GABAB positive allosteric modulator (PAM) candidate in treating chronic cough associated with idiopathic pulmonary fibrosis (IPF).
Gamma-amino-butyric acid (GABA) is the primary inhibitory neurotransmitter, activating ionotropic (GABAA) and metabotropic (GABAB) receptors. GABAB receptors occur in the peripheral cough neural circuit as well as in the lungs and airways. Targeting these receptors by allosteric modulation can reduce the severity of cough, also known as an antitussive effect.
In preclinical studies on bleomycin (BLM)-exposed animal models, a once-daily administration of the GABAB PAM candidate reduced cough frequency, and increased cough latency. The animal model receiving treatment showed reduced Ashcroft scores, indicating decreased percentage of affected lung tissue. The drug also exhibited a favorable safety profile.
ADXN closed Tuesday at $6.74, up 2.28%.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.